Elizabeth C. Cushman - 24 Feb 2026 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role: EVP, GC AND SECRETARY
Signature: /s/ Elizabeth C. Cushman, by Jessica H. Paik, Attorney-in-Fact
Issuer symbol: ABT
Transactions as of: 24 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 26 Feb 2026, 18:01:04 UTC
Previous filing: 01 Jul 2025
Next filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cushman Elizabeth C.	EVP, GC AND SECRETARY	100 ABBOTT PARK ROAD, ABBOTT PARK	/s/ Elizabeth C. Cushman, by Jessica H. Paik, Attorney-in-Fact	26 Feb 2026	0002075371

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABT	Common shares without par value	Award	$0	+15,031	+60%	$0.000000	40,257	24 Feb 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABT	Option (right to buy)	Award	$0	+61,964		$0.000000	61,964	24 Feb 2026	Common Shares	61,964	$114.60	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,654 on February 24, 2027, 20,655 on February 24, 2028, and 20,655 on February 24, 2029.